or Try an Advanced Search...

    ETF Components for HELX - Franklin Genomic Advancements ETF


    Below is a list of stocks held by this ETF. We only list holdings in the same market. If this is a global ETF, there may be additional components other than those listed here.

    Holdings

    Symbol Grade Price % Change Allocation
    MEDP C -0.33 7.39
    VRTX B -0.74 5.55
    REGN B -1.97 5.33
    LLY B -0.95 4.98
    DHR D -0.17 4.93
    TMO D 0.31 4.60
    KRYS C -0.03 4.44
    NTRA B 0.85 3.45
    AZN C -0.25 2.71
    MRNA D -0.96 2.60
    IONS B 1.02 2.54
    BRKR F 0.31 2.40
    CDNS B -0.41 2.34
    CTVA D -0.55 2.08
    CRL F -0.03 2.07
    SRPT C -0.71 2.00
    A D 0.28 2.00
    INSM C -3.88 1.92
    RCKT F 1.26 1.84
    QGEN D -0.29 1.80
    ICLR B -0.09 1.78
    ALNY A 0.43 1.67
    UTHR B -1.90 1.59
    BNTX F 1.40 1.31
    TWST C 1.44 1.29
    EXAS F 0.05 1.12
    FDMT D 1.31 1.10
    VYGR F 1.84 1.10
    AZTA D 0.82 1.04
    IQV F -0.32 1.04
    NBIX C 0.54 0.96
    TECH D 0.29 0.94
    NTLA F 3.61 0.93
    BBIO D 0.36 0.90
    RARE F -1.83 0.89
    BEAM D 4.03 0.85
    CRSP F 1.48 0.76
    LGND B -2.46 0.69
    RXRX F 2.65 0.67
    CDMO D 14.93 0.56
    RGEN F 0.52 0.49
    AVTR F 2.09 0.44
    BIO F 0.94 0.43
    SLP F -14.87 0.43
    ARE C 0.03 0.29
    BMY F -0.96 0.25
    DVAX F -0.54 0.21
    VCYT C 0.99 0.16
    OLK A 0.08 0.13

    Represented by ETF Holdings

    Keywords: Biotechnology S&P 500 Biology Life Sciences Biopharmaceutical Clinical Development Medicine Acid Cancer Lab Testing Amyloid Antibodies Cholesterol Drug Discovery In Vitro Infectious Diseases Nasdaq 100 Amyloidosis Asthma Chemical Compounds
    Industries: Biotechnology Diagnostics & Research Drug Manufacturers - Major Agricultural Inputs Health Information Services REIT - Office Semiconductor Equipment & Materials Software - Application Specialty Chemicals

    Recent News for Franklin Genomic Advancements ETF & its Holdings

    Date Stock Title
    Jul 3 TECH 'Breaking Up Google Would Drive 10%-15% Upside' For Shareholders, Analyst Says
    Jul 3 LLY Lilly's new Alzheimer's drug could generate $7.1B in sales: analyst
    Jul 3 LLY S&P 500, Nasdaq 100 Climb To Record Highs As Data Fosters Rate Cut Optimism Ahead Of Fed Minutes; Gold, Bonds Rally: What's Driving Markets Wednesday?
    Jul 3 MRNA GSK To Spend Up to $1.56B for Rights to Potential COVID-19, Flu Vaccines
    Jul 3 LLY Novo Nordisk, Eli Lilly Tumble After Study Suggests Weight-Loss Drugs Can Lead To Blindness
    Jul 3 LLY Weight-loss drugs linked to rare vision loss: Harvard study
    Jul 3 LLY ADP jobs data, Constellation Brands, summer gas prices: Morning Brief
    Jul 3 LLY Ozempic Linked to Rare Cases of Vision Loss in Harvard Study
    Jul 3 LLY FDA Approves Eli Lilly's Alzheimer's Drug Kisunla
    Jul 3 TECH Tesla Stock Soars On Q2 Delivery Beat: Chart Signals Strong Bullish Momentum
    Jul 3 MRNA GSK Will Pay Up to $1.5 Billion for CureVac’s mRNA Vaccines
    Jul 3 INSM Insmed Presenting More Positive Data for Prospective Drug Treatment for Bronchiectasis This Week
    Jul 3 SRPT 1 Soaring Growth Stock to Buy and Hold for 10 Years
    Jul 3 MRNA Moderna (MRNA) Secures BARDA Funding for Bird Flu Vaccine
    Jul 3 SRPT Best Momentum Stocks to Buy for July 3rd
    Jul 3 LLY Top 3 Health Care Stocks That May Crash This Quarter
    Jul 3 TECH Amazon Vs. Apple: The Showdown At All-Time Highs
    Jul 3 TECH Broadcom Up 10% Post-Stock Split: Strong Bullish Indicators With 12 Days To Go
    Jul 3 INSM Additional Positive Data from Pivotal ASPEN Study of Brensocatib in Patients with Bronchiectasis to be Presented at the 7th World Bronchiectasis Conference
    Jul 3 REGN Europe Approves Sanofi/Regeneron's Dupixent for 'Smoker's Lungs' A Month After US FDA Asks For Data
    Seeks capital appreciation by investing in innovative companies related to genomic-based technologies designed to enhance the quality of life. Provides access to companies benefitting from or facilitating the use of new research including DNA sequencing, gene editing and personalized medicine Uses bottom-up fundamental research conducted by dedicated, industry-specific analysts to identify disruptive business models at the right stage for investment Actively managed by a seasoned portfolio management team that is based in Silicon Valley and has a long history of investing in the craft of innovation
    Exchange Traded Fund ETF Biotechnology Life Sciences Biology Emerging Technologies Molecular Biology Genetics Portfolio Management Quality Of Life DNA Personalized Medicine DNA Sequencing
    Back to the Main HELX Page...